Biology of post-transplant relapse: actionable features

2.

Horowitz

M

,

Schreiber

H

,

Elder

A

, et al.

Epidemiology and biology of relapse after stem cell transplantation

.

Bone Marrow Transplant

.

2018

;

53

(

11

):

1379

-

1389

.

3.

Vago

L.

Clonal evolution and immune evasion in posttransplantation relapses

.

Hematology Am Soc Hematol Educ Program

.

2019

;

2019

(

1

):

610

-

616

.

4.

Maziarz

RT

,

Levis

M

,

Patnaik

MM

, et al.

Midostaurin after allogeneic stem cell transplant in patients with FLT3-internal tandem duplication-positive acute myeloid leukemia

.

Bone Marrow Transplant

.

2021

;

56

(

5

):

1180

-

1189

.

5.

Burchert

A

,

Bug

G

,

Fritz

LV

, et al.

Sorafenib maintenance after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia with FLT3-internal tandem duplication mutation (SORMAIN)

.

J Clin Oncol

.

2020

;

38

(

26

):

2993

-

3002

.

6.

Xuan

L

,

Wang

Y

,

Huang

F

, et al.

Sorafenib maintenance in patients with FLT3-ITD acute myeloid leukaemia undergoing allogeneic haematopoietic stem-cell transplantation: an open-label, multicentre, randomised phase 3 trial

.

Lancet Oncol

.

2020

;

21

(

9

):

1201

-

1212

.

7.

Levis

MJ

,

Hamadani

M

,

Logan

B

, et al;

BMT-CTN 1506/MORPHO Study Investigators

.

Gilteritinib as post-transplant maintenance for AML with internal tandem duplication mutation of FLT3

.

J Clin Oncol

.

2024

;

42

(

15

):

1766

-

1775

.

8.

Sandmaier

BM

,

Khaled

S

,

Oran

B

,

Gammon

G

,

Trone

D

,

Frankfurt

O.

Results of a phase 1 study of quizartinib as maintenance therapy in subjects with acute myeloid leukemia in remission following allogeneic hematopoietic stem cell transplant

.

Am J Hematol

.

2018

;

93

(

2

):

222

-

231

.

9.

Fischer

T

,

Stone

RM

,

Deangelo

DJ

, et al.

Phase IIB trial of oral midostaurin (PKC412), the FMS-like tyrosine kinase 3 receptor (FLT3) and multi-targeted kinase inhibitor, in patients with acute myeloid leukemia and high-risk myelodysplastic syndrome with either wild-type or mutated FLT3

.

J Clin Oncol

.

2010

;

28

(

28

):

4339

-

4345

.

10.

Metzelder

SK

,

Schroeder

T

,

Lübbert

M

, et al.

Long-term survival of sorafenib-treated FLT3-ITD-positive acute myeloid leukaemia patients relapsing after allogeneic stem cell transplantation

.

Eur J Cancer

.

2017

;

86

:

233

-

239

.

11.

Randhawa

JK

,

Kantarjian

HM

,

Borthakur

G

, et al.

Results of a phase II study of crenolanib in relapsed/refractory acute myeloid leukemia patients (pts) with activating FLT3 mutations

.

Blood

.

2014

;

124

(

21

):

389

.

12.

Perl

AE

,

Martinelli

G

,

Cortes

JE

, et al.

Gilteritinib or chemotherapy for relapsed or refractory FLT3-mutated AML

.

N Engl J Med

.

2019

;

381

(

18

):

1728

-

1740

.

13.

Cortes

JE

,

Khaled

S

,

Martinelli

G

, et al.

Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

.

Lancet Oncol

.

2019

;

20

(

7

):

984

-

997

.

14.

Fathi

AT

,

Kim

HT

,

Soiffer

RJ

, et al.

Enasidenib as maintenance following allogeneic hematopoietic cell transplantation for IDH2-mutated myeloid malignancies

.

Blood Adv

.

2022

;

6

(

22

):

5857

-

5865

.

15.

Fathi

AT

,

Kim

HT

,

Soiffer

RJ

, et al.

Multicenter phase I trial of ivosidenib as maintenance treatment following allogeneic hematopoietic cell transplantation for IDH1-mutated acute myeloid leukemia

.

Clin Cancer Res

.

2023

;

29

(

11

):

2034

-

2042

.

16.

de Botton

S

,

Fenaux

P

,

Yee

K

, et al.

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML

.

Blood Adv

.

2023

;

7

(

13

):

3117

-

3127

.

17.

Stein

EM

,

DiNardo

CD

,

Pollyea

DA

, et al.

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

.

Blood

.

2017

;

130

(

6

):

722

-

731

.

18.

DiNardo

CD

,

Stein

EM

,

de Botton

S

, et al.

Durable remissions with ivosidenib in IDH1-mutated relapsed or refractory AML

.

N Engl J Med

.

2018

;

378

(

25

):

2386

-

2398

.

19.

Zucenka

A

,

Issa

GC

,

Arellano

M

, et al.

Revumenib maintenance therapy following revumenib-induced remission and transplant

.

Blood

.

2023

;

142

(

suppl 1

):

4950

.

20.

Issa

GC

,

Aldoss

I

,

DiPersio

J

, et al.

The menin inhibitor revumenib in KMT2A- rearranged or NPM1-mutant leukaemia

.

Nature

.

2023

;

615

(

7954

):

920

-

924

.

21.

Hong

S

,

Rybicki

L

,

Gurnari

C

, et al.

Pattern of somatic mutation changes after allogeneic hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes

.

Bone Marrow Transplant

.

2022

;

57

(

10

):

1615

-

1619

.

22.

Quek

L

,

Ferguson

P

,

Metzner

M

, et al.

Mutational analysis of disease relapse in patients allografted for acute myeloid leukemia

.

Blood Adv

.

2016

;

1

(

3

):

193

-

204

.

23.

Wienecke

CP

,

Heida

B

,

Venturini

L

, et al.

Clonal relapse dynamics in acute myeloid leukemia following allogeneic hematopoietic cell transplantation

.

Blood

.

2024

;

144

(

3

):

296

-

307

.

24.

Christopher

M

,

Petti

AA

,

Miller

C

, et al.

Clonal evolution of acute myeloid leukemia following allogeneic stem cell transplantation

.

Blood

.

2016

;

128

(

22

):

1528

.

25.

Waterhouse

M

,

Pfeifer

D

,

Pantic

M

,

Emmerich

F

,

Bertz

H

,

Finke

J.

Genome-wide profiling in AML patients relapsing after allogeneic hematopoietic cell transplantation

.

Biol Blood Marrow Transplant

.

2011

;

17

(

10

):

1450

-

1459.e11459e1

.

26.

Mathew

NR

,

Baumgartner

F

,

Braun

L

, et al.

Sorafenib promotes graft- versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

.

Nat Med

.

2018

;

24

(

3

):

282

-

291

.

27.

Vosberg

S

,

Hartmann

L

,

Metzeler

KH

, et al.

Relapse of acute myeloid leukemia after allogeneic stem cell transplantation is associated with gain of WT1 alterations and high mutation load

.

Haematologica

.

2018

;

103

(

12

):

e581

-

e584

.

28.

Tameni

A

,

Toffalori

C

,

Vago

L.

Tricking the trickster: precision medicine approaches to counteract leukemia immune escape after transplant

.

Blood

.

2024

;

143

(

26

):

2710

-

2721

.

29.

Zeiser

R

,

Vago

L.

Mechanisms of immune escape after allogeneic hematopoietic cell transplantation

.

Blood

.

2019

;

133

(

12

):

1290

-

1297

.

30.

Rovatti

PE

,

Gambacorta

V

,

Lorentino

F

,

Ciceri

F

,

Vago

L.

Mechanisms of leukemia immune evasion and their role in relapse after haploidentical hematopoietic cell transplantation

.

Front Immunol

.

2020

;

11

:

147

.

31.

Vago

L

,

Perna

SK

,

Zanussi

M

, et al.

Loss of mismatched HLA in leukemia after stem-cell transplantation

.

N Engl J Med

.

2009

;

361

(

5

):

478

-

488

.

32.

Toffalori

C

,

Cavattoni

I

,

Deola

S

, et al.

Genomic loss of patient-specific HLA in acute myeloid leukemia relapse after well-matched unrelated donor HSCT

.

Blood

.

2012

;

119

(

20

):

4813

-

4815

.

33.

Crucitti

L

,

Crocchiolo

R

,

Toffalori

C

, et al.

Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

.

Leukemia

.

2015

;

29

(

5

):

1143

-

1152

.

34.

Vago

L

,

Toffalori

C

,

Ahci

M

, et al.

Incidence of HLA loss in a global multicentric cohort of post-transplantation relapses: results from the Hlaloss Collaborative Study

. Blood.

2018

;

132

:

818

.

35.

Muñiz

P

,

Kwon

M

,

Carbonell

D

, et al.

Clinical utility of the detection of the loss of the mismatched HLA in relapsed hematological patients after haploidentical stem cell transplantation with high-dose cyclophosphamide

.

Front Immunol

.

2021

;

12

:

642087

.

36.

Mazzi

B

,

Clerici

TD

,

Zanussi

M

, et al.

Genomic typing for patient-specific human leukocyte antigen-alleles is an efficient tool for relapse detection of high-risk hematopoietic malignancies after stem cell transplantation from alternative donors

.

Leukemia

.

2008

;

22

(

11

):

2119

-

2122

.

37.

Ahci

M

,

Toffalori

C

,

Bouwmans

E

, et al.

A new tool for rapid and reliable diagnosis of HLA loss relapses after HSCT

.

Blood

.

2017

;

130

(

10

):

1270

-

1273

.

38.

Wu

H

,

Shi

J

,

Luo

Y

, et al.

Assessment of patient-specific human leukocyte antigen genomic loss at relapse after antithymocyte globulin-based T-cell-replete haploidentical hematopoietic stem cell transplant

.

JAMA Netw Open

.

2022

;

5

(

4

):

e226114

.

39.

Rovatti

PE

,

Zito

L

,

Draghi

E

, et al.

Exploiting an anti-CD3/CD33 bispecific antibody to redirect donor T cells against HLA loss leukemia relapses

.

Blood

.

2019

;

134

(

suppl 1

):

513

.

40.

Wu

H

,

Cai

Z

,

Shi

J

,

Luo

Y

,

Huang

H

,

Zhao

Y.

Blinatumomab for HLA loss relapse after haploidentical hematopoietic stem cell transplantation

.

Am J Cancer Res

.

2021

;

11

(

6

):

3111

-

3122

.

41.

Toffalori

C

,

Zito

L

,

Gambacorta

V

, et al.

Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation

.

Nat Med

.

2019

;

25

(

4

):

603

-

611

.

42.

Christopher

MJ

,

Petti

AA

,

Rettig

MP

, et al.

Immune escape of relapsed AML cells after allogeneic transplantation

.

N Engl J Med

.

2018

;

379

(

24

):

2330

-

2341

.

43.

Geramita

E

,

Ventura

K

,

Bhise

S

, et al.

Pilot trial of interferon-γ and donor lymphocyte infusion to treat relapsed myeloblastic malignancies after allogeneic hematopoietic stem cell transplantation

.

Transplant Cell Ther

.

2023

;

29

:

S45

-

S46

.

44.

Rimando

JC

,

Chendamarai

E

,

Rettig

MP

, et al.

Flotetuzumab and other T-cell immunotherapies upregulate MHC class II expression on acute myeloid leukemia cells

.

Blood

.

2023

;

141

(

14

):

1718

-

1723

.

45.

Gambacorta

V

,

Beretta

S

,

Ciccimarra

M

, et al.

Integrated multiomic profiling identifies the epigenetic regulator PRC2 as a therapeutic target to counteract leukemia immune escape and relapse

.

Cancer Discov

.

2022

;

12

(

6

):

1449

-

1461

.

46.

Noviello

M

,

Manfredi

F

,

Ruggiero

E

, et al.

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT

.

Nat Commun

.

2019

;

10

(

1

):

1065

.

47.

Norde

WJ

,

Maas

F

,

Hobo

W

, et al.

PD-1/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation

.

Cancer Res

.

2011

;

71

(

15

):

5111

-

5122

.

48.

Zhou

M

,

Sacirbegovic

F

,

Zhao

K

,

Rosenberger

S

,

Shlomchik

WD

.

T cell exhaustion and a failure in antigen presentation drive resistance to the graft-versus-leukemia effect

.

Nat Commun

.

2020

;

11

(

1

):

4227

.

49.

Penter

L

,

Zhang

Y

,

Savell

A

, et al.

Molecular and cellular features of CTLA-4 blockade for relapsed myeloid malignancies after transplantation

.

Blood

.

2021

;

137

(

23

):

3212

-

3217

.

50.

Davids

MS

,

Kim

HT

,

Bachireddy

P

, et al;

Leukemia and Lymphoma Society Blood Cancer Research Partnership

.

Ipilimumab for patients with relapse after allogeneic transplantation

.

N Engl J Med

.

2016

;

375

(

2

):

143

-

153

.

51.

Garcia

JS

,

Flamand

Y

,

Penter

L

, et al.

Ipilimumab plus decitabine for patients with MDS or AML in posttransplant or transplant-naïve settings

.

Blood

.

2023

;

141

(

15

):

1884

-

1888

.

52.

Davids

MS

,

Kim

HT

,

Costello

C

, et al.

A multicenter phase 1 study of nivolumab for relapsed hematologic malignancies after allogeneic transplantation

.

Blood

.

2020

;

135

(

24

):

2182

-

2191

.

53.

Godfrey

J

,

Liu

H

,

Yu

J

, et al.

Pembrolizumab for the treatment of disease relapse after allogeneic hematopoietic stem cell transplantation

.

Blood Adv

.

2023

;

7

(

6

):

963

-

970

.

54.

Apostolova

P

,

Kreutmair

S

,

Toffalori

C

, et al.

Phase II trial of hypomethylating agent combined with nivolumab for acute myeloid leukaemia relapse after allogeneic haematopoietic cell transplantation—Immune signature correlates with response

.

Br J Haematol

.

2023

;

203

(

2

):

264

-

281

.

55.

Sallman

DA

,

McLemore

AF

,

Aldrich

AL

, et al.

TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype

.

Blood

.

2020

;

136

(

24

):

2812

-

2823

.

56.

Lau

CM

,

Nish

SA

,

Yogev

N

,

Waisman

A

,

Reiner

SL

,

Reizis

B.

Leukemia-associated activating mutation of Flt3 expands dendritic cells and alters T cell responses

.

J Exp Med

.

2016

;

213

(

3

):

415

-

431

.

57.

Uhl

FM

,

Chen

S

,

O'Sullivan

D

, et al.

Metabolic reprogramming of donor T cells enhances graft-versus-leukemia effects in mice and humans

.

Sci Transl Med

.

2020

;

12

(

567

):

eabb8969

.

58.

Vallet

N

,

Le Grand

S

,

Bondeelle

L

, et al.

Azithromycin promotes relapse by disrupting immune and metabolic networks after allogeneic stem cell transplantation

.

Blood

.

2022

;

140

(

23

):

2500

-

2513

.

59.

Peled

JU

,

Devlin

SM

,

Staffas

A

, et al.

Intestinal microbiota and relapse after hematopoietic-cell transplantation

.

J Clin Oncol

.

2017

;

35

(

15

):

1650

-

1659

.

60.

Karl

F

,

Liang

C

,

Böttcher-Loschinski

R

, et al.

Oxidative DNA damage in reconstituting T cells is associated with relapse and inferior survival after allo-SCT

.

Blood

.

2023

;

141

(

13

):

1626

-

1639

.

61.

Naka

K

,

Hoshii

T

,

Muraguchi

T

, et al.

TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia

.

Nature

.

2010

;

463

(

7281

):

676

-

680

.

62.

Lee

YJ

,

Han

Y

,

Lu

HT

, et al.

TGF-beta suppresses IFN-gamma induction of class II MHC gene expression by inhibiting class II transactivator messenger RNA expression

.

J Immunol

.

1997

;

158

(

5

):

2065

-

2075

.

63.

Park

HH

,

Kim

M

,

Lee

B-H

, et al.

Intracellular IL-4, IL-10, and IFN-gamma levels of leukemic cells and bone marrow T cells in acute leukemia

.

Ann Clin Lab Sci

.

2006

;

36

(

1

):

7

-

15

.

64.

DiLillo

DJ

,

Weinberg

JB

,

Yoshizaki

A

, et al.

Chronic lymphocytic leukemia and regulatory B cells share IL-10 competence and immunosuppressive function

.

Leukemia

.

2013

;

27

(

1

):

170

-

182

.

65.

Munn

DH

,

Sharma

MD

,

Baban

B

, et al.

GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase

.

Immunity

.

2005

;

22

(

5

):

633

-

642

.

66.

Mussai

F

,

De Santo

C

,

Abu-Dayyeh

I

, et al.

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

.

Blood

.

2013

;

122

(

5

):

749

-

758

.

67.

Caravagna

G

,

Heide

T

,

Williams

MJ

, et al.

Subclonal reconstruction of tumors by using machine learning and population genetics

.

Nat Genet

.

2020

;

52

(

9

):

898

-

907

.

68.

Bacher

U

,

Haferlach

T

,

Alpermann

T

, et al.

Comparison of cytogenetic clonal evolution patterns following allogeneic hematopoietic transplantation versus conventional treatment in patients at relapse of AML

.

Biol Blood Marrow Transplant

.

2010

;

16

(

12

):

1649

-

1657

.

69.

Pagliuca

S

,

Gurnari

C

,

Hercus

C

, et al.

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantation

.

Nat Commun

.

2023

;

14

(

1

):

3153

.